Laboratory of Nutrigenomics, Inflammation and Obesity Research, Department of Nutritional Sciences, Texas Tech University (TTU), Lubbock, TX, USA; Obesity Research Institute, Texas Tech University, Lubbock, TX, USA.
Laboratory of Nutrigenomics, Inflammation and Obesity Research, Department of Nutritional Sciences, Texas Tech University (TTU), Lubbock, TX, USA; Obesity Research Institute, Texas Tech University, Lubbock, TX, USA; Laboratory of Immunopharmacology, Department of Immunology, Institute of Biomedical Sciences, University of Sao Paulo (ICB/USP), São Paulo, SP, Brazil; Laboratory of Immunoendocrinology, Department of Clinical and Toxicological Analyses, School of Pharmaceutical Sciences, University of Sao Paulo (FCF/USP), São Paulo, SP, Brazil.
Mol Cell Endocrinol. 2021 May 15;528:111245. doi: 10.1016/j.mce.2021.111245. Epub 2021 Mar 20.
The Renin-Angiotensin System (RAS) is classically recognized for regulating blood pressure and fluid balance. Recently, this role has extended to other areas including inflammation, obesity, diabetes, as well as breast cancer. RAS components are expressed in normal and cancerous breast tissues, and downregulation of RAS inhibits metastasis, proliferation, angiogenesis, and desmoplasia in the tumor microenvironment. Therefore, RAS inhibitors (Angiotensin receptor blockers, ARBs, or angiotensin converting enzyme inhibitors, ACE-I) may be beneficial as preventive adjuvant therapies to thwart breast cancer development and improve outcomes, respectively. Given the beneficial effects of RAS inhibitors in metabolic diseases, which often co-exist in breast cancer patients, combining RAS inhibitors with other breast cancer therapies may enhance the effectiveness of current treatments. This review scrutinizes above associations, to advance our understanding of the role of RAS in breast cancer and its potential for repurposing of RAS inhibitors to improve the therapeutic approach for breast cancer patients.
肾素-血管紧张素系统 (RAS) 经典上被认为可以调节血压和体液平衡。最近，它的作用已经扩展到其他领域，包括炎症、肥胖、糖尿病以及乳腺癌。RAS 成分在正常和癌性乳腺组织中表达，下调 RAS 可抑制肿瘤微环境中的转移、增殖、血管生成和纤维组织增生。因此，RAS 抑制剂（血管紧张素受体阻滞剂、ARB 或血管紧张素转换酶抑制剂、ACE-I）可能作为预防辅助疗法有益于阻止乳腺癌的发展并改善结局。鉴于 RAS 抑制剂在代谢疾病中的有益作用，这些疾病通常与乳腺癌患者并存，将 RAS 抑制剂与其他乳腺癌疗法相结合可能会提高现有治疗方法的有效性。本综述深入研究了这些关联，以增进我们对 RAS 在乳腺癌中的作用的理解，并探讨将 RAS 抑制剂重新用于改善乳腺癌患者治疗方法的潜力。
